Peroxisome Proliferator-Activated Receptor γ (PPAR-γ) agonist rosiglitazone (RGZ) inhibits HL-60 cell growth by induction of apoptosis

Laboratory Medicine

Volumn 40, Issue 5, 2009, Pages 297-302

  Liu, Jia Jun ^a   Yan Xu, ^a   Zhang, Yong ^a   Xiao, Ruo Zhi ^a   Lin, Dong Jun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN BAX; PROTEIN BCL 2; ROSIGLITAZONE; SURVIVIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN HL 60; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

EID: 77952001243     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LMOTQ5MUG76FMYMK     Document Type: Article

References (36)

1. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta. 2007;1771:915-925.
2. Bocher V, Chinetti G, Fruchart JC. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. J Soc Biol. 2002;196:47-52.
3. Issemann I, Green S. Activation of a member of the steriodhormone receptor superfamily by peroxisome proliferators. Nature. 1990;3:645-650. (Pubitemid 20356241)
4. Evans RM, Barish GD. PPARs and the complex journey to obesity. Nat Med. 2004;10:355-361.
5. Wang T, Xu J, Yu X, et al. Peroxisome proliferator-activated receptor γ in malignant diseases. Crit Rev Oncol Hematol. 2006;58:1-14.
6. Ulivieri C, Baldari CT. The potential of peroxisome proliferator- activated receptor gamma (PPAR gamma) ligands in the treatment of hematological malignancies. Mini Rev Med Chem. 2007;7:877-887. (Pubitemid 47554778)
7. Nagasawa E, Abe Y, Nishimura J, et al. Pivotal role of peroxisome proliferator-activated receptor gamma (PPARgamma) in regulation of erythroid progenitor cell proliferation and differentiation. Exp Hematol. 2005;33:857-864 (Pubitemid 40982651)
8. Ray DM, Spinelli SL, Pollock SJ, et al. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost. 2008;99:86-95.
9. Amoruso A, Bardelli C, Gunella G, et al. A novel activity for substance P: Stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages. Br J Pharmacol. 2008;154:144-152. (Pubitemid 351620392)
10. Liu J, Lu H, Huang R, et al. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol. 2005;56:400-408. (Pubitemid 41095403)
11. Inoue S, Snowden RT, Dyer MJ, et al. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia. 2004;18:948-952. (Pubitemid 38714619)
12. Coyle AT, O'Keeffe MB, Kinsella BT. 15-deoxy Delta12,14-prostaglandin J2 suppresses transcription by promoter 3 of the human thromboxane A2 receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J. 2005;272:4754-4773.
13. Coyle AT, Kinsella BT. Synthetic peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone suppress transcription by promoter 3 of the human thromboxane A2 receptor gene in human erythroleukemia cells. Biochem Pharmacol. 2006;71:1308-1323.
14. Liu H, Zang C, Fenner MH. Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18. Blood. 2006;107:3683-3692.
15. Piva R, Gianferretti P, Ciucci A. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: An effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood. 2005;105:1750-1758. (Pubitemid 40223699)
16. Schimmer AD. Induction of apoptosis in lymphoid and myeloid leukemia. Curr Oncol Rep. 2006;8:430-436. (Pubitemid 44697772)
17. Chawla-Sarkar M, Lindner DJ, Liu YF. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8:237-249. (Pubitemid 36749609)
18. Del Poeta G, Bruno A, Del Principe MI, et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets. 2008;8:207-222. (Pubitemid 351666857)
19. Lacombe F, Belloc F. Flow cytometry study of cell cycle, apoptosis and drug resistance in acute leukemia. Hematol Cell Ther. 1996;38:495-504. (Pubitemid 27022461)
20. Debatin KM. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother. 2004;53:153-197.
21. Levine B, Sinha S, Kroemer G. Bcl-2 family members: Dual regulators of apoptosis and autophagy. Autophagy. 2008;4:600-606.
22. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene. 2003;22:8590-8607 (Pubitemid 38028528)
23. Daniel PT, Schulze-Osthoff K, Belka C. Guardians of cell death: The Bcl-2 family proteins. Essays Biochem. 2003;39:73-88. (Pubitemid 37457072)
24. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004; 644:229-249.
25. Manion MK, Hockenbery DM. Targeting Bcl-2-related proteins in cancer therapy. Cancer Biol Ther. 2003; 2:S105-114.
26. Smolewski P, Darzynkiewicz Z, Robak T. Caspase-mediated cell death in hematological malignancies: Theoretical considerations, methods of assessment, and clinical implications. Leuk Lymphoma. 2003;44:1089-1104.
27. Denault JB, Salvesen GS. Caspases: Keys in the ignition of cell death. Chem Rev. 2002;102:4489-4500.
28. Philchenkov AA. Caspases as regulators of apoptosis and other cell functions. Biochemistry. 2003;68:365-376.
29. Qi SN, Yoshida A, Ueda T. Activation of caspases-3/7 is dispensable for idarubicin-induced apoptotic DNA fragmentation in human leukemia cells. Int J Oncol. 2003;22:1123-1128.
30. Boatright KM, Salvesen GS. Caspase activation. Biochem Soc Symp. 2003;70:233-242.
31. Donepudi M, Grutter MG. Structure and zymogen activation of caspases. Biophys Chem. 2002;101:145-153.
32. Mazumder S, Plesca D, Almasan A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol Biol. 2008;414:13-21.
33. Mita AC, Mita MM, Nawrocki ST, et al. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000-5005.
34. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61-70.
35. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: Molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999-6002. (Pubitemid 47037475)
36. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4:174-191. (Pubitemid 350171819)